Compare MAMA & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | JSPR |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.8M | 48.1M |
| IPO Year | N/A | N/A |
| Metric | MAMA | JSPR |
|---|---|---|
| Price | $14.02 | $1.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $17.00 | ★ $21.44 |
| AVG Volume (30 Days) | 647.0K | ★ 3.9M |
| Earning Date | 12-08-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.91 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $151,312,000.00 | N/A |
| Revenue This Year | $35.43 | N/A |
| Revenue Next Year | $28.82 | N/A |
| P/E Ratio | $117.59 | ★ N/A |
| Revenue Growth | ★ 29.92 | N/A |
| 52 Week Low | $5.50 | $1.39 |
| 52 Week High | $14.97 | $22.99 |
| Indicator | MAMA | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 71.15 | 51.88 |
| Support Level | $11.04 | $1.61 |
| Resistance Level | $14.97 | $1.93 |
| Average True Range (ATR) | 0.78 | 0.22 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 75.04 | 45.15 |
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.